Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation

Recruiting now · Not applicable

Conditions studied: Covid19, Olfactory Dysfunction

In brief

Investigation of the mechanisms of persistent SARS-CoV-2 associated olfactory dysfunction (OD) in patients with well-documented olfactory function. The investigators plan to collect olfactory cleft biopsies and cytobrushes in COVID-19 patients and controls.

Key facts

Study ID

NCT06482138

Run by

Universitaire Ziekenhuizen KU Leuven

People needed

240

Starts

2024-01-24

Expected to finish

2026-12-31

Last updated by the study team

2026-05-06

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Olfactory Dysfunction group: Presence of evident OD (Parosmia, Threshold-Discrimination-Identification (TDI)-score ≤24, Subjective abnormal quantitative olfactory function; measured by a visual analogue score (VAS) of smell impairment ≥5/10
• Control group: No OD (TDI-score \>30.5.)

You may not qualify if…

• Presence of concomitant nasal mucosal pathology that might affect olfactory function or bias the study investigations
• Use of anticoagulation therapy
• Allergy to local anesthetics

Where it is running

• University Hospital Carl Gustav Carus — Dresden, Dresden, Germany (enrolling)
• UZ/KU Leuven — Leuven, Vlaams-Brabant, Belgium (enrolling)
• AZ Sint-Jan Brugge — Bruges, West-Vlaanderen, Belgium (enrolling)
• Cliniques Universitaires Saint-Luc — Brussels, Brussels Capital, Belgium (enrolling)
• University of Zurich and University Hospital Zurich — Zurich, Canton of Zurich, Switzerland (enrolling)
• Hôpitaux Universitaires de Genève — Geneva, Canton of Geneva, Switzerland (enrolling)
• Max Planck Research Unit for Neurogenetics — Frankfurt am Main, Frankfurt, Germany

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.